Mediterr J Rheumatol 2018;29(4):221-3
68-year old woman with refractory cutaneous dermatomyositis
Authors Information
1. Patras University Hospital, Department of Internal Medicine, Division of Rheumatology, Rion, Patras, Greece
2. University of Patras Medical School, Rion, Patras, Greece
  1. Majithia V, Harisdangkul V. Mycophenolate mofetil (CellCept): An alternative therapy for autoimmune inflammatory myopathy. Rheumatology 2005;44(3):386-9. [https://doi.org/10.1093/rheumatology/keh499] [PMID: 15572389]
  2. Rowin J, Amato AA, Deisher N, Cursio J, Meriggioli MN. Mycophenolate mofetil in dermatomyositis: Is it safe? Neurology 2006;66(8):1245-7. [https://doi.org/10.1212/01.wnl.0000208416.32471.c0] [PMID: 16636243]
  3. Tausche AK, Meurer M. Mycophenolate mofetil for dermatomyositis. Dermatology 2001;202(4):341-3. [https://doi.org/10.1159/000051674] [PMID: 11455153]
  4. Ytterberg SR. Treatment of refractory polymyositis and dermatomyositis. Curr Rheumatol Rep 2006;8(3):167-73. [PMID: 16901073]
  5. Lang BA, Laxer RM, Murphy G, Silverman ED, Roifman CM. Treatment of dermatomyositis with intravenous gammaglobulin. Am J Med 1991;91(2):169-72. [PMID: 1714236]
  6. Cherin P, Herson S, Wechsler B, Piette JC, Bletry O, Coutellier A, et al. Efficacy of intravenous gammaglobulin therapy in chronic refractory polymyositis and dermatomyositis: An open study with 20 adult patients. Am J Med 1991;91(2):162-8. [PMID: 1714235]
  7. Kampylafka EI, Kosmidis ML, Panagiotakos DB, Dalakas M, Moutsopoulos HM, Tzioufas AG. The effect of intravenous immunoglobulin (IVIG) treatment on patients with dermatomyositis: A 4-year follow-up study. Clin Exp Rheumatol 2012;30(3):397-401. [PMID: 22510247]
  8. Basta M, Dalakas MC. High-dose intravenous immunoglobulin exerts its beneficial effect in patients with dermatomyositis by blocking endomysial deposition of activated complement fragments. J Clin Invest 1994;94(5):1729-35. [https://doi.org/10.1172/JCI117520] [PMID: 7962520] [PMCID: PMC294563]
  9. Dalakas MC, Illa I, Dambrosia JM, Soueidan SA, Stein DP, Otero C, et al. A Controlled Trial of High-Dose Intravenous Immune Globulin Infusions as Treatment for Dermatomyositis. N Engl J Med [Internet] 1993;329(27):1993-2000. Available from: http://www.nejm.org/doi/abs/10.1056/NEJM199312303292704[https://doi.org/10.1056/NEJM199312303292704] [PMID: 8247075]
  10. Amemiya K, Semino-Mora C, Granger RP, Dalakas MC. Downregulation of TGF-β1 mRNA and protein in the muscles of patients with inflammatory myopathies after treatment with high-dose intravenous immunoglobulin. Clin Immunol 2000;94(2):99-104. [https://doi.org/10.1006/clim.1999.4823] [PMID: 10637094]
  11. Levine TD. Rituximab in the treatment of dermatomyositis: An open-label pilot study. Arthritis Rheum 2005;52(2):601-7. [https://doi.org/10.1002/art.20849] [PMID: 15692974]
  12. Cooper MA, Willingham DL, Brown DE, French AR, Shih FF, White AJ. Rituximab for the treatment of juvenile dermatomyositis: A report of four pediatric patients. Arthritis Rheum 2007;56(9):3107-11. [https://doi.org/10.1002/art.22856] [PMID: 17763414]